
Shuxin Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2698401/publications.pdf Version: 2024-02-01



SHUYIN HUANC

#	Article	IF	CITATIONS
1	Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML. Biomarker Research, 2020, 8, 6.	6.8	54
2	TOX as a potential target for immunotherapy in lymphocytic malignancies. Biomarker Research, 2021, 9, 20.	6.8	34
3	A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia. Journal of Leukocyte Biology, 2019, 106, 725-732.	3.3	24
4	Higher frequency of the CTLAâ€4 ⁺ LAGâ€3 ⁺ Tâ€cell subset in patients with newly diagnosed acute myeloid leukemia. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e12-e18.	1.1	18
5	Increasing Timâ€3+CD244+, Timâ€3+CD57+, and Timâ€3+PDâ€1+ TÂcells in patients with acute myeloid leukem Asia-Pacific Journal of Clinical Oncology, 2020, 16, 137-141.	ia 1.1	17
6	Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 740642.	2.8	15
7	Increased TOX expression associates with exhausted T cells in patients with multiple myeloma. Experimental Hematology and Oncology, 2022, 11, 12.	5.0	10
8	Increased <scp>TOX</scp> expression concurrent with <scp>PD</scp> â€1, Timâ€3, and <scp>CD244</scp> expression in T cells from patients with acute myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2022, 102, 143-152.	1.5	10
9	Increased TOX expression concurrent with PDâ€1, Timâ€3, and CD244 in T cells from patients with nonâ€Hodgkin lymphoma. Asia-Pacific Journal of Clinical Oncology, 2021, , .	1.1	9